• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Emergent BioSolutions Inc.

    11/13/24 4:00:18 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EBS alert in real time by email
    SC 13G 1 p24-3235sc13g.htm EMERGENT BIOSOLUTIONS INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No.)*
     

    Emergent BioSolutions Inc.

    (Name of Issuer)
     

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    29089Q105

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 6 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 29089Q10513GPage 2 of 6 Pages

     

    1

    NAME OF REPORTING PERSON

    Oak Hill Advisors, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)¨

    (b)¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    3,613,338 shares of Common Stock (including 2,500,000 shares of Common Stock issuable upon exercise of warrants)

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    3,613,338 shares of Common Stock (including 2,500,000 shares of Common Stock issuable upon exercise of warrants)

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,613,338 shares of Common Stock (including 2,500,000 shares of Common Stock issuable upon exercise of warrants)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.39%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

    CUSIP No. 29089Q10513GPage 3 of 6 Pages

     

     

    Item 1(a). NAME OF ISSUER:
       
     

    Emergent BioSolutions Inc. (the “Company”)

       
    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
       
      300 Professional Drive, Gaithersburg, MD 20879.
       
    Item 2(a). NAME OF PERSON FILING:
       
      This Schedule 13G is being filed on behalf of Oak Hill Advisors, L.P., a Delaware limited partnership (“OHA” or, the “Reporting Person”), as investment adviser to certain funds and client accounts (directly or through an affiliate) (together, the “Oak Hill Funds”), with respect to the shares of Common Stock and the shares of  Common Stock issuable upon exercise of warrants directly held by the Oak Hill Funds.
       
      OHA is a subsidiary business of T. Rowe Price Associates, Inc. (“TRP”).  OHA’s beneficial ownership does not include any shares that may be beneficially owned by TRP.
       
      Glenn R. August, a United States citizen, is the Founder and Chief Executive Officer of OHA.
       
      Any disclosures herein with respect to persons other than the Reporting Person are made on information and belief after making inquiry to the appropriate party.  The filing of this statement should not be construed in and of itself as an admission by the Reporting Person as to beneficial ownership of the securities reported herein.
       
    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of the Reporting Person is One Vanderbilt Avenue, 16th Floor, New York, New York 10017.
       
    Item 2(c). CITIZENSHIP:
       
      OHA is a Delaware limited partnership.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.001 per share (the “Common Stock”)

     

    Item 2(e). CUSIP NUMBER:
       
      29089Q105

     

     

    CUSIP No. 29089Q10513GPage 4 of 6 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:______________________________

     

    Item 4. OWNERSHIP:
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page and is incorporated herein by reference.
       
      The percentage set forth in Row 11 of the cover page for the Reporting Person is calculated based upon 54,019,962 shares of  Common Stock, which is the sum of (i) 52,906,624 shares of Common Stock outstanding as of July 30, 2024, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 7, 2024 and (ii) 1,113,338 shares of Common Stock issued by the Company on September 17, 2024, as disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 17, 2024, and assumes the exercise of warrants reported herein.

     

    CUSIP No. 29089Q10513GPage 5 of 6 Pages

     

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
      See Item 2. The Oak Hill Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON:
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.

     

    Item 10. CERTIFICATION:
       
      The Reporting Person hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
         

     

     

    CUSIP No. 29089Q10513GPage 6 of 6 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: November 13, 2024

     

    oak hill advisors, l.p.  
       
    By: /s/ Gregory S. Rubin  
    Name: Gregory S. Rubin  
    Title: Authorized Signatory  
         
         

     

    Get the next $EBS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EBS

    DatePrice TargetRatingAnalyst
    12/30/2024$15.00Buy
    H.C. Wainwright
    8/22/2024$16.00Buy
    Rodman & Renshaw
    3/7/2024$5.00Hold → Buy
    The Benchmark Company
    11/20/2023Underweight
    JP Morgan
    8/29/2023Buy → Hold
    The Benchmark Company
    4/10/2023$22.00Hold → Buy
    The Benchmark Company
    3/17/2023$23.00 → $9.00Neutral → Underweight
    JP Morgan
    11/10/2022Buy → Hold
    The Benchmark Company
    More analyst ratings

    $EBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dayal Sujata Tyagi was granted 25,344 shares and sold $115,610 worth of shares (13,761 units at $8.40) as part of a pre-agreed trading plan, increasing direct ownership by 13% to 100,563 units (SEC Form 4) (withholding obligation)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    5/4/26 5:30:54 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Degolyer Donald W was granted 25,344 shares and sold $129,994 worth of shares (15,481 units at $8.40) as part of a pre-agreed trading plan, increasing direct ownership by 8% to 129,721 units (SEC Form 4) (withholding obligation)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    5/4/26 5:30:24 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Katkin Keith was granted 25,344 shares and sold $128,183 worth of shares (15,481 units at $8.28) as part of a pre-agreed trading plan, increasing direct ownership by 11% to 96,294 units (SEC Form 4) (withholding tax)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    5/4/26 5:29:30 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day to Help Save Lives from Opioid Overdose

    GAITHERSBURG, Md., June 04, 2026 (GLOBE NEWSWIRE) -- In honor of National Naloxone Awareness Day on June 6th, Emergent BioSolutions Inc. (NYSE:EBS) is teaming up with Victoria's Voice Foundation – which launched the awareness day with bipartisan congressional support – to spread awareness and encourage action against the ongoing opioid epidemic. Serving as a tribute to Victoria Siegel and all those lost to overdoses, Victoria's Voice is continuing the "Shine. Wear. Share. Care." Campaign, which promotes education and preparedness by distributing purple light bulbs (Shine), wearable promotional items (Wear), encouraging social media participation via QR codes with #sharenaloxone (Share), an

    6/4/26 8:02:00 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy

    GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States Department of Health and Human Services (HHS), for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]. The modification has been made to the existing 10-year contract with ASPR (75A50119C00075) whereby Emergent will supply BAT®, an antitoxin used in the treatment of symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G

    5/28/26 4:01:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions to Participate in Upcoming Investor Conferences

    GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that members of the company's senior management team will participate in the following investor conferences: Goldman Sachs 11th Annual Leveraged Finance and Credit Conference, May 27-29Benchmark 6th Annual Healthcare House Call Virtual Investor Conference, May 28Jefferies Global Healthcare Conference, June 2-4 June 3: presentation and webcast, 1:20-1:50 p.m. eastern time, register here. Goldman Sachs 47th Annual Global Healthcare Conference, June 8-10 June 8: presentation and webcast, 2:00-3:00 p.m. eastern time, register here. Please contact a conference repr

    5/20/26 7:30:00 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Emergent BioSolutions with a new price target

    H.C. Wainwright initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $15.00

    12/30/24 7:24:57 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Emergent BioSolutions with a new price target

    Rodman & Renshaw initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $16.00

    8/22/24 7:22:39 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded Emergent BioSolutions from Hold to Buy and set a new price target of $5.00

    3/7/24 10:14:18 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Papa Joseph C bought $349,800 worth of shares (60,000 units at $5.83), increasing direct ownership by 21% to 342,500 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    5/15/25 4:02:40 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    SEC Filings

    View All

    SEC Form 144 filed by Emergent BioSolutions Inc.

    144 - Emergent BioSolutions Inc. (0001367644) (Subject)

    5/1/26 4:03:11 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Emergent BioSolutions Inc.

    S-8 - Emergent BioSolutions Inc. (0001367644) (Filer)

    4/30/26 4:41:26 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Emergent BioSolutions Inc. (0001367644) (Filer)

    4/30/26 4:32:09 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Leadership Updates

    Live Leadership Updates

    View All

    Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

    GAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026. Mr. Fowler brings more than three decades of leadership experience across the healthcare and financial services sectors. He will serve on the Audit and Finance Committee. "We're pleased to welcome John to the board of directors at this important point in the company's ongoing turnaround and transformation," said Dr. Zsolt Harsanyi, Ph.D., chairman of the board. "John's deep experience in healthcare and financial markets will provide valuable insight as the company continues to execute against i

    3/3/26 8:00:00 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

    GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) announced today that Dr. Louis W. Sullivan will retire from the company's Board of Directors effective November 14 after 19 years of service to the company and its shareholders. "For nearly two decades, Dr. Sullivan has been a trusted advisor and champion of Emergent's mission to protect and save lives," said Joe Papa, president and CEO of Emergent. "On behalf of the Board and the entire Emergent team, I want to thank him for his distinguished leadership and contributions. We wish him all the best." Dr. Sullivan served on Emergent's Board of Directors since 2006, and most recently served as chair of the

    11/12/25 4:01:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

    Executive Management Team appointments contribute to Emergent's transformation and beyond, including promotion of Jessica Perl to General Counsel and Corporate Secretary GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced the appointment of Simon Lowry, M.D., as chief medical officer, head of research and development, effective November 18. Dr. Lowry will be responsible for advancing Emergent's strategic scientific roadmap, and will oversee research and development, regulatory affairs, medical affairs, clinical an

    11/4/24 7:30:00 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Financials

    Live finance-specific insights

    View All

    Emergent BioSolutions Reports First Quarter 2026 Financial Results

    First Quarter 2026 Total Revenues of $156.1 millionFirst Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4%First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA Margin of 23% GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the first quarter ended March 31, 2026. "Emergent's first quarter results demonstrate a strong and positive start to 2026, with healthy topline revenue of $156 million, above the high-end of our guidance range, and adjusted EBITDA of $36 million," said Joe Papa, president and CEO of Emergent. "We are further strengthening our financial position in 202

    4/30/26 4:30:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

    GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, April 30, 2026, at 5:00 p.m. eastern time to discuss the financial results for the first quarter of 2026. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can b

    4/16/26 4:05:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

    Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior yearFull Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior yearFull Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior yearFull Year 2025 Adjusted Net Income per diluted share of $1.53 versus an Adjusted Net Loss per diluted share of $0.23 in the prior yearFull Year 2025 Gross Margin % of 45% and Adjusted Gross Margin % of

    2/26/26 4:05:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Emergent BioSolutions Inc.

    SC 13G - Emergent BioSolutions Inc. (0001367644) (Subject)

    11/13/24 4:00:18 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Emergent BioSolutions Inc.

    SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)

    11/8/24 5:23:28 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Emergent BioSolutions Inc.

    SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)

    9/10/24 12:09:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care